10-Q: Rigel Pharmaceuticals Reports Strong Q3 2025 Revenue Growth

Rigel Pharmaceuticals announced significant revenue growth in the third quarter of 2025, driven by strong product sales across its commercial portfolio, despite the termination of a key CNS development program with Lilly.

Summary

• Net income for the three months ended September 30, 2025, increased by 124.6% to $27.9 million, up from $12.4 million in the same period in 2024.
• Total revenues for the three months ended September 30, 2025, grew by 25.6% to $69.5 million, compared to $55.3 million in the prior year period.
• Net product sales for the three months ended September 30, 2025, surged by 64.6% to $64.1 million, from $38.9 million in the same period in 2024.
• For the nine months ended September 30, 2025, total revenues increased by 84.5% to $224.5 million, and net income reached $99.0 million, a substantial increase from $3.1 million in the prior year period.
• TAVALISSE net product sales for the nine months ended September 30, 2025, were $113.3 million, a 54% increase compared to $73.8 million in the same period in 2024.
• REZLIDHIA net product sales for the nine months ended September 30, 2025, were $21.4 million, a 38% increase compared to $15.6 million in the same period in 2024.
• GAVRETO, which began commercialization in late June 2024, generated $31.9 million in net product sales for the nine months ended September 30, 2025.
• Cash, cash equivalents, and short-term investments totaled $137.1 million as of September 30, 2025.
• The company settled patent litigation with Annora Pharma, granting a license to sell a generic version of TAVALISSE in the second quarter of 2032 or earlier.
• Eli Lilly and Company provided notice of its intent to terminate the central nervous system (CNS) disease program under their collaboration agreement, effective 60 days following notification on October 1, 2025.
• Rigel opted out of co-funding ocadusertib development, resulting in a $40.0 million non-cash revenue recognition in the second quarter of 2025.
• The R289 dual IRAK1/4 inhibitor program for lower-risk myelodysplastic syndrome (MDS) completed dose escalation in July 2025, with the first patient enrolled in the dose expansion part in October 2025.

Sentiment

Score: 8

Explanation: The company demonstrated robust financial growth with significant increases in product sales and net income, and made progress in its clinical pipeline. However, the termination of the Lilly CNS program and a new safety signal for GAVRETO introduce some headwinds and uncertainties. The overall financial health and pipeline advancements are strong, but tempered by these challenges.

Positives

• Achieved significant financial growth with net income increasing by 124.6% to $27.9 million for Q3 2025 and total revenues growing by 25.6% to $69.5 million.
• Reported substantial year-to-date net income of $99.0 million for the nine months ended September 30, 2025, a significant improvement from $3.1 million in the prior year.
• Experienced strong product sales growth, with TAVALISSE increasing 54% to $113.3 million and REZLIDHIA increasing 38% to $21.4 million for the nine months ended September 30, 2025.
• GAVRETO, a recently commercialized product, contributed $31.9 million in net product sales for the nine months ended September 30, 2025.
• Successfully settled patent litigation for TAVALISSE with Annora Pharma, securing market exclusivity until Q2 2032 or earlier.
• The R289 program for lower-risk MDS received Orphan Drug designation (January 2025) and Fast Track designation (November 2024) from the FDA, indicating regulatory support and potential for expedited development.
• Preliminary data for R289 in lower-risk MDS showed general tolerability and preliminary signs of efficacy, with 31% of evaluable transfusion-dependent patients achieving durable RBC-transfusion independence for >8 weeks at doses of at least 500 mg once daily.
• Strategic collaborations with MDACC and CONNECT are expanding the evaluation of olutasidenib in AML, other hematologic cancers, and high-grade glioma (HGG).
• The accumulated deficit was significantly reduced from $(1,390.1) million as of December 31, 2024, to $(1,291.1) million as of September 30, 2025.
• Net cash provided by operating activities for the nine months ended September 30, 2025, increased substantially to $53.7 million from $17.0 million in the prior year period.
• Maintained a healthy liquidity position with $137.1 million in cash, cash equivalents, and short-term investments as of September 30, 2025.

Negatives

• Contract revenues from collaborations decreased by 67% to $5.4 million for the three months ended September 30, 2025, compared to $16.4 million in the same period in 2024.
• Eli Lilly and Company provided notice of its intent to terminate the CNS disease program under the Lilly Agreement, meaning Rigel will not be entitled to receive any future milestone and royalty payments associated with this program.
• Knight Therapeutics International SA received a rejection from the Brazilian Health Regulatory Agency (ANVISA) regarding its marketing authorization application for fostamatinib in Brazil, with an appeal process that may take up to 14 months.
• A new safety signal was identified in an ongoing Phase 3 clinical trial of GAVRETO (pralsetinib) in first-line RET fusion-positive, metastatic NSCLC patients, requiring enhanced monitoring for signs and symptoms of infection.
• An initial positive efficacy report for one R289 patient in the Phase 1b study was later determined to be a non-responder due to uncaptured blood transfusions, highlighting potential data analysis discrepancies in interim results.
• Net cash, cash equivalents, and restricted cash decreased by $8.155 million for the nine months ended September 30, 2025, compared to an increase of $18.906 million in the prior year period.

Risks

• Prospects are highly dependent on existing commercial products; diminished commercial success could adversely affect business, financial condition, and stock price.
• Inability to successfully develop or commercialize product candidates if problems arise in clinical testing and/or the approval process.
• There is a high risk that drug discovery and development efforts might not generate successful product candidates.
• The strategy to expand the hematology and oncology pipeline through acquisitions or in-licensing may not be successful.
• Products may become subject to unfavorable pricing regulations, health technology assessments (HTA), third-party payor reimbursement practices, or labeling restrictions, which vary by country.
• Inability to successfully market and distribute products and retain experienced commercial personnel.
• Subject to stringent and evolving healthcare regulatory, privacy, and information security laws, with potential for significant investigations, fines, penalties, and claims for non-compliance.
• If manufacturers obtain approval for generic versions of products, or of products with which Rigel competes, the business may be harmed.
• Unforeseen safety issues could emerge with products, requiring changes to prescribing information, limiting product use, and/or resulting in litigation.
• Reliance on third-party distribution facilities for product sales, which could face disruptions.
• Lack of internal manufacturing capability and reliance on third parties for commercial supply, manufacturing, and distribution, with risks of timely, cost-effective, or quality supply.
• Any product for which regulatory approval has been obtained, or for which approval is obtained in the future, is subject to extensive ongoing regulatory requirements; failure to comply or unanticipated problems may lead to penalties, inability to generate revenue, diminished cash flow, and increased capital needs.
• Unsuccessful corporate collaborations or failure to form new ones could delay research and development efforts.
• Success is dependent on securing intellectual property rights and data exclusivity, which is complex and uncertain.
• Disputes regarding the infringement or misappropriation of the proprietary rights of others could be costly and result in delays in research and development, partnering, and commercialization activities.
• If competitors develop technologies that are more effective than Rigel's, commercial opportunity will be reduced or eliminated.
• Product liability lawsuits, if successfully brought against the company, may incur substantial liabilities and require limiting commercialization of products.
• Market opportunities for products and product candidates may be smaller than believed.
• Difficulties with managing organizational growth could adversely affect business and results of operations.
• Global economic conditions, including military conflicts (e.g., Russian-Ukrainian war, Hamas-Israel war) and trade policies, could adversely impact the business.
• Bank failures or other events affecting financial institutions could adversely impact liquidity and other business operations.
• Shareholder activism and private securities-related litigation could cause material disruption to the business.
• Anti-takeover provisions in charter documents and under Delaware law may make an acquisition of the company more difficult.
• Increasing use of social media could give rise to liability and may harm the business.
• Dependence on various scientific consultants and advisors for the success and continuation of research and development efforts.
• Use of biological and hazardous materials in a manner that causes injury or violates laws may lead to liability for damages, penalties, or fines.
• Information technology systems, or those used by CROs or other contractors/consultants, may fail or suffer other breakdowns, cyber-attacks, or information security breaches.
• Future equity issuances or a sale of a substantial number of shares of common stock may cause the price of common stock to decline.
• Enacted or future legislation, and/or potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost to obtain regulatory approval and/or commercialize products, and affect the prices that may be set or obtained.
• Regulatory approval for any approved product is limited to specific indications and conditions; promoting off-label use could incur significant liability.
• Delays in clinical testing could result in increased costs.
• Public perception of the risk-benefit balance for product candidates may be affected by adverse events in clinical trials involving the product candidate or other treatments.
• The ability to use net operating losses (NOLs) and certain other tax attributes is uncertain and may be limited.
• Changes in valuation allowance of deferred tax assets may affect future operating results.

Future Outlook

Rigel Pharmaceuticals expects to continue leveraging its existing commercial infrastructure for GAVRETO and anticipates future revenues from existing and new commercial products, collaboration partners, and government grants. The company projects continued significant research and development expenses for its IRAK1/4 inhibitor program and olutasidenib collaborations. Management believes existing capital resources will be sufficient for at least the next 12 months. The company plans to expand olutasidenib evaluation through additional strategic collaborations and Rigel-led studies and will present updated R289 data at the 67th ASH Annual Meeting in December 2025. Regulatory and legislative changes, including the new EU HTA Regulation, UK Cyber Security and Resilience Bill, and EU AI regulation, are expected to impact the industry in the coming years.

Management Comments

• "Based on our current operating plan, we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Form 10-Q."
• "We expect to continue to leverage our existing commercial infrastructure to ensure current and newly prescribed GAVRETO patients have continued access to this important treatment option."
• "We expect that our future revenues to include product sales of our existing commercial products and product sales from new commercial products we may have in the future."
• "We expect to continue to incur significant research and development expense as we continue our activities in our clinical studies including IRAK1/4 inhibitor program; our collaborative partnerships with MDACC and CONNECT to evaluate olutasidenib in AML, other hematologic cancers and glioma; and any other clinical programs we may pursue in the future."
• "We expect to incur significant selling, general and administrative expenses, and expect our commercial related expenses to increase as we continue to expand our commercial activities."

Industry Context

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid technological change. Rigel's products, TAVALISSE, REZLIDHIA, and GAVRETO, operate in markets with existing therapies and strong competition from larger pharmaceutical companies. The industry faces increasing governmental and public scrutiny over drug pricing, patient assistance programs, and evolving global privacy and information security regulations (e.e., GDPR, CCPA, NISD2, AI Act). Healthcare reform initiatives in the US, such as the Inflation Reduction Act and changes to the 340B Program, continue to exert pressure on drug pricing and reimbursement. There is also a growing emphasis on corporate responsibility and ESG factors by investors and regulators, which could influence investment strategies and compliance burdens.

Comparison to Industry Standards

• TAVALISSE is highlighted as the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
• REZLIDHIA is presented as a novel, non-intensive monotherapy treatment in the R/R AML setting, demonstrating a CR+CRh rate of 35% with over 90% of responders in complete remission, and an extended median duration of complete response of 28.1 months, which is more than a year longer than what is reported with the standard of care (e.g., TIBSOVO).
• GAVRETO is noted as one of only two approved RET inhibitors on the market for patients with RET fusion-positive non-small cell lung cancer (NSCLC) and advanced thyroid cancers, competing with Lilly's selpercatinib (Retevmo).
• The R289 program for lower-risk MDS showed preliminary signs of efficacy in a heavily pretreated patient population, with 4 out of 13 (31%) evaluable transfusion-dependent patients achieving durable RBC-transfusion independence for >8 weeks at doses of at least 500 mg once daily, indicating a potential threshold for dose response similar to observed LPS-induced inhibition in healthy volunteers.

Corporate Governance

Legal Proceedings

• Entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. (collectively, Annora) in March 2025, resolving patent litigation related to TAVALISSE. Under the terms, Annora will have a license to sell its generic product in the second quarter of 2032 or earlier under certain circumstances. All ongoing litigation between Rigel and Annora regarding TAVALISSE patents pending in New Jersey was terminated as of March 26, 2025.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue and net income growth, reduced accumulated deficit, and pipeline progress. Potential for dilution from future equity raises. Risks associated with the termination of the Lilly CNS program and the GAVRETO safety signal.
• Patients: Continued access to TAVALISSE, REZLIDHIA, and GAVRETO. Potential for new treatment options from the R289 program and expanded olutasidenib evaluations.
• Employees: Stable to growing employment opportunities due to strong financial performance and ongoing research and development activities. Potential for increased workload due to growth and compliance requirements.
• Collaboration Partners: Eli Lilly and Company's termination of the CNS program impacts future milestone and royalty payments for Rigel. Kissei and Dr. Reddys collaborations continue. Knight's marketing authorization application for fostamatinib in Brazil was rejected, requiring an appeal.
• Creditors: Improved financial health and liquidity, along with a reduced accumulated deficit, generally reduce credit risk. However, the company has significant loan principal payments due in the near term.

Next Steps

• Present updated data from the dose escalation phase of the R289 Phase 1b study at the 67th ASH Annual Meeting and Exposition, to be held December 6-9, 2025.
• Continue enrollment in the dose expansion part of the R289 Phase 1b study, randomizing patients to receive either 500 mg once daily or 500 mg twice daily.
• Continue clinical development efforts for olutasidenib through strategic collaborations with MDACC and CONNECT, including five studies open for enrollment.
• Eli Lilly and Company will continue to advance ocadusertib in its Phase 2a clinical trial for rheumatoid arthritis.
• Knight Therapeutics International SA will pursue an appeal regarding the rejection of its marketing authorization application for fostamatinib in Brazil, which may take up to 14 months.
• Evaluate the impact of recently issued accounting standards, including ASU 2023-09 (Improvements to Income Tax Disclosures), ASU 2024-03 (Income StatementReporting Comprehensive IncomeExpense Disaggregation Disclosures), and ASU 2025-05 (Measurement of Credit Losses for Accounts Receivable and Contract Assets).
• Monitor the implementation of the 340B Rebate Model Pilot Program, intended to become effective January 1, 2026.
• Monitor the implementation of new UK and EU regulations, including the Data (Use and Access) Bill, the EU Network and Information Systems Security 2 Directive (NISD2), the EU Critical Entities Resilience Directive (CER), the EU Data Act, the European Health Data Space Regulation (EHDS), and the EU AI Act.

Key Dates

Recommendation

The company demonstrates strong financial performance with significant revenue and net income growth, driven by its commercial products TAVALISSE, REZLIDHIA, and GAVRETO. The reduction in accumulated deficit and positive operating cash flow are encouraging. Pipeline progress with R289 and strategic collaborations for olutasidenib add long-term potential. However, the termination of the Lilly CNS program, the GAVRETO safety signal, and the rejection of Knight's MAA in Brazil introduce uncertainties. While the financial results are strong, these headwinds and the competitive landscape warrant a 'hold' recommendation, suggesting investors monitor ongoing developments closely before making further investment decisions.

Keywords

Rigel Pharmaceuticals, RIGL, biotechnology, hematologic disorders, cancer, TAVALISSE, fostamatinib, ITP, REZLIDHIA, olutasidenib, AML, IDH1 mutation, GAVRETO, pralsetinib, NSCLC, thyroid cancer, RET fusion, R289, IRAK1/4 inhibitor, MDS, clinical trials, FDA approval, orphan drug, Fast Track, SEC filing, 10-Q, financial results, product sales, collaboration revenue, intellectual property, patent litigation, healthcare regulation, cybersecurity